

## ISRM Portfolio Directors' Panel Discussion

October 16, 2024





## Panel Members

- Patricia Dorn, Executive Director, Rehabilitation R&D & Translation
- Amy Kilbourne, Executive Director, Health Systems Research
- ➤ Holly Krull, Acting Executive Director, Medical Health Research
- Kenute Myrie, Director, Precision Oncology Actively Managed Portfolio
- Miriam Smyth, Acting Executive Director, Brain, Behavioral and Mental Health Research
- Christopher Bever, Deputy Chief R&D Officer for ISRM (Moderator)



# In 2025 ORD will celebrate its 100-year anniversary!



## **Record of Accomplishments:**

- First R-C clinical trial
- Cardiac pacemaker
- First liver transplant
- Seattle foot
- Deka arm
- Multiple Nobel Laureates









# Preparing VA Research for the Next 100 Years

- > Organizing research funding around areas of Veteran need
- > Adopting a shared governance model in ORD
- > Adopting NIH approach to Notices of Funding Opportunities
- > Harmonizing our processes across the portfolios




# Organizing Funding Around Areas of Veteran Need





## How the service-based structure addressed Veteran needs



A Area of Veteran Need A B Veteran Need B C Veteran Need C

This partial drawing of ORD's structure is for illustration purposes only






## The New Structure and Shared Governance

## Leadership Council

**Shared Governance** 



## **Actively Managed Portfolios**

Focused purviews

## **Broad Portfolios**

**Broad purviews** 





# Scientific Review Groups have been assigned to the Broad Portfolios

Brain, Behavioral & Mental Health	<b>Health Systems Research</b>	Medical Health	Rehabilitation R&D & Translation
HSR4: Mental and Behavioral Health	HSR1: Health Care & Clinical	CARA/B: Cardiology	RRDA: Spinal Cord Injuries/Disorders &
MHBA: Preclinical Mental Health	Management	CAMM: Cellular &	Neuropathic Pain
MHBC: Clinical Mental Health	HSR2: Behavioral, Social &	Molecular Medicine,	<b>RRD0:</b> Regenerative Rehabilitation Medicine
MHBP: PTSD	Cultural Determinants of Health	Geroscience	RRD2: Musculoskeletal Health & Injury
NURA: Substance Abuse	HSR3: Health Care	ENDA: Endocrinology,	RRD3: Sensory Systems & Communications
NURB: Peripheral Neuropathy & Epilepsy	Informatics	ENDB: Frailty,	Disorders
NURC: SCI & TBI	HSR5: Health Care System	musculoskeletal health	RRD5: Rehabilitation Engineering &
	Organization & Delivery and	GAST: Gastroenterology	Prosthetics/Orthotics
<b>NURD:</b> Alzheimer's Disease, Dementia, Aging Brain, Neurodegeneration and Cognitive Dysfunction	Women's Health	<b>HEMA:</b> Hematology	RRD6: Chronic Medical Conditions & Aging
<b>NURE:</b> Movement Disorders, Parkinson's,	HSR6: Long Term Care &	IMMA: Immunology	RRD7: Research Career Scientist
Huntington's, ALS, Dystonia, Neurodegeneration	Aging & Support Services	INFA/B: Infectious Diseases	RRD8: Career Development Program- Panel 1
NURF: Sensory Dysfunction	<b>HSR7:</b> Special Emphasis	<b>NEPH:</b> Nephrology	RRD9: Career Development Program – Panel
NURR: Sleep	Topics	ONCA/B/C/D/E: Oncology	2
NURP: Pain	HSR8: QUERI	PULM: Pulmonology	RRDC: Centers/REAPs
RRD1/B: Brain Health	HQ5, HQ8: QUERI	SPLD: GW	
RRD4: Behavioral Health & Social Reintegration		SURG: Surgery	





# Winter – Summer Cycle Scientific Review Groups

Brain, Behavioral & Mental Health	Health Systems Research	Medical Health	Rehabilitation R&D & Translation
HSR4: Mental and Behavioral Health  MHBA: Preclinical Mental Health	HSR1: Health Care & Clinical Management	CARA/B: Cardiology CAMM: Cellular &	RRDA: Spinal Cord Injuries/Disorders & Neuropathic Pain
MHBC: Clinical Mental Health	<b>HSR2:</b> Behavioral, Social & Cultural Determinants of	Molecular Medicine, Geroscience	RRD0: Regenerative Rehabilitation Medicine RRD2: Musculoskeletal Health & Injury
NURA: Substance Abuse	Health  HSR3: Health Care	ENDA: Endocrinology, ENDB: Frailty,	RRD3: Sensory Systems & Communications Disorders
NURB: Peripheral Neuropathy & Epilepsy NURC: SCI & TBI	Informatics  HSR5: Health Care System  Organization & Delivery and	musculoskeletal health  GAST: Gastroenterology	RRD5: Rehabilitation Engineering & Prosthetics/Orthotics
NURD: Alzheimer's Disease, Dementia, Aging Brain, Neurodegeneration and Cognitive Dysfunction	Women's Health  HSR6: Long Term Care &	HEMA: Hematology IMMA: Immunology	RRD6: Chronic Medical Conditions & Aging RRD7: Research Career Scientist
NURE: Movement Disorders, Parkinson's, Huntington's, ALS, Dystonia, Neurodegeneration	Aging & Support Services  HSR7: Special Emphasis	INFA/B: Infectious Diseases NEPH: Nephrology	RRD8: Career Development Program - Panel 1 RRD9: Career Development Program - Panel
NURF: Sensory Dysfunction  NURR: Sleep	Topics  HSR8: QUERI	ONCA/B/C/D/E: Oncology	2  RRDC: Centers/REAPs
NURP: Pain  RRD1/B: Brain Health	HQ5, HQ8: QUERI	PULM: Pulmonology SPLD: GW	
RRD4: Behavioral Health & Social Reintegration		SURG: Surgery	






# ORD Shared Governance Model





# ISRM Leadership Council



#### • Structure:

 DCRADO, Director of Research Integration, Director of Operations Portfolio Directors, Program Directors are voting members

#### Functions:

- Oversight of portfolio activities
- Promoting cross-portfolio communications
- Communication with ORD leadership

# Portfolio Funding Process

 The budget for each portfolio is determined by the ISRM Leadership Council at the beginning of each fiscal year.

Value of projects from end of the prior fiscal year

+

- Additional specific funding provided in ORD budget
- The ISRM LC has the authority to transfer funds between portfolios during the fiscal year if required.



# **Project Funding Process**

 Applications for funding will be reviewed in either the standing scientific review groups or the special review groups.

Portfolios will hold funding ranking meetings for each review cycle.

 Ranked lists with funding recommendations will be submitted for approval to the Leadership Council.



# Adopting NIH Approach to NOFOs





# New Cross-Portfolio RFAs Posted 9/3

RFAs	Pre-Applications	
Career Development Award 1 (IK1)	Pre-Application – Career Development Award (IK1/IK2)	
Career Development Award 2 (IK2)		
Research Career Scientist (IK6)	Pre-Application – Research Career Scientist (IK6)	
Pilot Research (I21)	Pre-Application – Pilot (I21)	
Parent Merit Review – Clinical Trials (101)	Pre-Application – Parent Merit Clinical Trial (I01)	
Parent Merit Review – Non-Clinical Trials (101)	Pre-Application – Parent Merit Non-Clinical Trials (I01)	
CORE (I50)	Pre-Application – CORE (I50)	





# Portfolio Notices of Special Interest Posted 9/3

### Based upon Portfolio purviews

Brain, Behavior, and Mental Health Broad Portfolio

Health Systems Broad Portfolio

Medical Health Broad Portfolio

Rehabilitation Broad Portfolio

Military Exposure Actively Managed Portfolio

Pain / Opioid Use Actively Managed Portfolio

Precision Oncology Actively Managed Portfolio

Suicide Prevention Actively Managed Portfolio

Traumatic Brain Injury Actively Managed Portfolio

Gulf War

### Critical Research Areas/Cross Portfolio

Women's Health

Durability of Rehabilitation Interventions for Veterans

Chronic Effects of Neurotrauma

Studies on Lethal Means Safety Approaches to Suicide Prevention





# Harmonizing Processes Across the Portfolios





## New Review Timeline

	Winter	Spring	Summer	Fall
Site waivers for 2 <sup>nd</sup> new NCI slot	N/A	10/15	N/A	4/15
CT, CDA, TT Pre-apps due	8/1 (W24: 10/1)	11/1	2/1	5/1
MVP data use apps due	10/1	1/1	4/1	7/1
Other Research Pre- apps due	11/1	2/1	5/1	8/1
DTTW deadline for full apps	12/8	3/8	6/8	9/8
eRA closes to full apps	12/10	3/10	6/10	9/10



# Pre-application due dates and pre-application notification to investigators for the current winter cycle slightly differ by RFA

# Career Development 1 &2, Research including Clinical Trials, and Tech Transfer Key Dates:

9/3: 7 RFAs and NOSIs posted

**10/1:** Pre-applications for relevant scientific review groups (SRGs)\* due

11/1: Investigators notified of the status of their pre-application (accepted, rejected, or assigned to a new SRG or Portfolio)

**12/8:** Final date to submit full application

**March 2025:** Summary scores and statements released to investigators

Research Career Scientist, Pilot Award, Research not including Clinical Trials, and CORE RFAs Key Dates:

9/3: 7 RFAs and NOSIs posted

11/1: Pre-applications for relevant scientific review groups (SRGs)\* due

11/22: Investigators notified of the status of their pre-application (accepted, rejected, or assigned to a new SRG or Portfolio)

**12/8:** Final date to submit full application

March 2025: Summary scores and statements released to investigators

\*A listing of winter cycle SRGs are located in the Appendix





# RFA for Merit Award including an interventional clinical trial

Budget Item	Limit for Single Site	Limit for Multi-VAMC Sites*
Budget Cap	•For two (2) years: \$600,000 •For three (3) years: \$900,000 •For four (4) years: \$1,200,000	For a 2-site a total:  •For two (2) years, \$600,000  •For three (3) years, \$1,125,000  •For four (4) or five (5) years, \$1,500,000  For a 3 or more sites a total:  •Additional \$100,000 per site per year for each additional site added to total budget cap
Duration	Up to four (4) years	Up to five (5) years

Budget cap waivers approved by the ISRM Leadership Council

# RFA for Merit Award not including an interventional clinical trial

- PI may receive funding for up to 3 Merit awards
- Non-clinician PI salary, 3/8 allowed above the cap. Any additional salary requirements must be taken from the research award.
- \$200K per year cap for up to 4 years
- Waivers approved by the ISRM Leadership Council



# Takeaways on Application Review Process Revisions for Investigators



#### What has changed

- Funding opportunities are organized by the type of research proposed.
- Accepted Pre-Applications are required prior to any full application submission for most applications.
- Pre-applications are submitted to the cross-portfolio pre-application RFAs (IO2).
- The scientific review groups review for all Portfolios (not just a single Service).
- Scored proposals will be ranked in the Portfolio funding meeting.
- The ranked applications will go to the ISRM Leadership Council which will provide oversight and final approvals.
- Funded projects will be managed by the SPM who managed the review working with the director of the Portfolio to which it was submitted.

# Takeaways on Application Review Process Revisions for Investigators




#### What has NOT changed

- RFAs are posted and applications are submitted through Grants.gov and eRA Commons.
- ORD-wide RFAs will still support the full range of research activities and disciplines.
- The purview of scientific review groups (SRGs) and timing of SRG meetings (every 6 months).
- The Scientific Portfolio Managers who manage the SRGs have not changed.
- Review by a specific scientific review group can be requested.
- Applications not funded may be resubmitted no more than 2 times (-A1 and -A2).
- Once a decision has been made about an application, a notice of intent to fund or not to fund will be sent.
- PIs with approved applications will be required to complete just-in-time requirements.
- If funded, the SPM who managed the review of the application will manage your project.

## Conclusion

- On October 1, 2024, ISRM transitioned from four Services to nine Portfolios.
- Service RFAs have been replaced by cross-portfolio RFAs and portfolio Notices of Special Interest
- Peer-review panels (SRGs) will remain the same.
- Portfolio funding recommendations will be reviewed by the ISRM Leadership Council which will have representation from all portfolios.

# In 2025 ORD will celebrate its 100-year anniversary!



## Preparing for the next 100 years!

- New organizational structure built around Veteran needs and designed to improve health system performance.
- New processes to accelerate innovation, speed implementation and rapidly respond to changing requirements.

